Clinical Trials

134 enrolled

Carcinoma, Renal Cell

NCT04071236 2026-03-18

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

90 enrolled

Phase 1 Active not recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

Phase 3 Completed

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT04489719 2026-02-17

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Recruiting

48 enrolled

Prostatic Neoplasms

NCT05133440 2026-01-21

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

12 enrolled

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

2 enrolled

Prostatic Neoplasms

NCT02141438 2025-10-16

REASSURE

1,472 enrolled 18 charts

Metastatic Castration-resistant Prostate Cancer

NCT03737370 2025-10-07

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

43 enrolled

Prostatic Neoplasms

NCT04521361 2025-09-19

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

46 enrolled

Bone Metastatic Castration-resistant Prostate Cancer

NCT03361735 2025-05-02

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled

Prostate Adenocarcinoma

NCT03304418 2025-04-30

RROPE

20 enrolled 14 charts

Prostate Cancer Metastatic to Bone

NCT03076203 2025-04-29

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

14 enrolled

Prostate Carcinoma Metastatic to the Bone

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02043678 2025-02-19

ERA 223

Phase 3 Completed

806 enrolled 32 charts

Prostatic Neoplasms

NCT03002220 2024-12-11

EXCAAPE

52 enrolled 15 charts

Prostatic Neoplasms

NCT03996473 2024-10-10

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Phase 1 Terminated

8 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04232761 2024-07-17

RAPIT

194 enrolled

Castration-resistant Prostate Cancer

NCT04587427 2024-03-08

DIRECT

1,067 enrolled

Bone Metastatic Castration-resistant Prostate Cancer

NCT03315260 2024-02-08

Treatment Satisfaction With Ra-223 in Japan

85 enrolled

Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

40 enrolled 18 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04256993 2024-01-16

PRECISE

1,434 enrolled

Prostatic Neoplasms, Fractures, Bone

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast

Breast Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

122 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04681144 2023-10-26

QOLRAD

103 enrolled

GenitourinarySarcoma

Bone Neoplasms, Prostatic Neoplasms

NCT05301062 2023-09-22

CREDIT

Terminated

8 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05771896 2023-09-14

CARE

Phase 3 Withdrawn

Prostatic Neoplasms

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

100 enrolled

Hormone Refractory Prostate Cancer

NCT02346526 2022-09-29

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

22 enrolled 14 charts

Prostatic Neoplasms

NCT02582749 2022-07-11

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Phase 2 Terminated

16 enrolled 6 charts

Prostatic Neoplasms

NCT03223597 2022-04-15

ROTOR

300 enrolled

Pain

NCT04516161 2022-03-31

EPIX

1,180 enrolled

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03896984 2021-12-29

PHENIX

346 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02398526 2021-11-02

PARABO

363 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02450812 2021-11-02

URANIS

86 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

45 enrolled 7 charts

Breast

Breast Neoplasms

NCT03062254 2021-09-21

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

14 enrolled

Prostatic Neoplasms

NCT04995614 2021-08-09

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

122 enrolled

Fatigue

NCT02283749 2021-02-02

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

5 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03458559 2020-11-17

RaRe

Phase 3 Unknown

402 enrolled

Prostatic Neoplasms

NCT02199197 2020-10-30

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

49 enrolled 18 charts

Prostatic Neoplasms

NCT03419442 2020-10-22

Multi-academic Center Study of Xofigo Patients

150 enrolled

Prostatic Neoplasms

NCT02258464 2020-08-10

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Terminated

99 enrolled 18 charts

Breast

Breast Neoplasms

NCT03563014 2020-05-20

BELFIGO

164 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02899104 2020-03-31

Navigant

200 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02406521 2020-03-04

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

30 enrolled

Carcinoma, Renal Cell

NCT02928029 2020-02-26

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Phase 1/2 Terminated

7 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT02925702 2020-01-27

PRORADIUM

Unknown

161 enrolled

Advanced Prostate Cancer

NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

45 enrolled